Amarin Corp PLC ADR
![Amarin Corp PLC ADR](https://api.admiralmarkets.com/trade_icons/bright-128/AMRN.png)
Suletud
0.59 -1.67
Ülevaade
Aktsiahinna muutus
24h
Min
0.58
Max
0.6
Sissetulek | 11M 1.5M |
---|---|
Müük | 11M 67M |
Aktsiakasum | 0.01 |
Kasumimarginaal | 2.252 |
EBITDA | 13M 237K |
Soovitused | Müü |
---|---|
12 kuu keskmine prognoos | +66.67 upside |
Järgmine tulemuste avaldamine | 30. okt 2024 |
---|
Turukapital | 8M 257M |
---|---|
Eelmine avamishind | 2.26 |
Eelmine sulgemishind | 0.59 |
Tehniline skoor
By Trading Central
Kindlus
Bearish Evidence
Amarin Corp PLC ADR Graafik
Seotud uudised
Võrdlus sarnastega
Hinnamuutus
Amarin Corp PLC ADR Prognoos
Hinnasiht
By TipRanks
66.67% tõus
12 kuu keskmine prognoos
Keskmine 1 USD 66.67%
Kõrge 1 USD
Madal 1 USD
Põhineb 2 Wall Streeti analüütiku instrumendi Amarin Corp PLC ADR 12 kuu hinnasihil - viimase 3 kuu andmed.
Finantsandmed
Müügi- ja halduskulud
Tegevuskulud
Maksueelne kasum
Müük
Müügikulu
Brutokasum müügist
Intressikulud võla pealt
EBITDA
Ärikasum
$
Ettevõttest Amarin Corp PLC ADR
Amarin Corporation plc is a biopharmaceutical company with operations in lipid science focused on the commercialization and development of therapeutics for cardiovascular health. The Company operates through the development and commercialization of Vascepa segment. The Company's lead product, Vascepa (icosapent ethyl) capsule, is approved by the United States Food and Drug Administration (FDA) for use as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia. This indication for Vascepa, known as the MARINE indication, is based primarily on the results from the MARINE study of Vascepa in this approved patient population. The Company sells Vascepa principally to wholesalers, as well as selected regional wholesalers and specialty pharmacy providers, or collectively, its distributors, which in turn resell Vascepa to retail pharmacies for resale to patients and healthcare providers.